128 related articles for article (PubMed ID: 36241000)
1. Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia.
Zhang M; Ge Y; Xu S; Fang X; Meng J; Yu L; Wang C; Liu J; Wen T; Yang Y; Wang C; Xu H
Pharmacol Res; 2022 Nov; 185():106503. PubMed ID: 36241000
[TBL] [Abstract][Full Text] [Related]
2. Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.
Meng J; Ge Y; Xing H; Wei H; Xu S; Liu J; Yan D; Wen T; Wang M; Fang X; Ma L; Yang Y; Wang C; Wang J; Xu H
Small; 2020 Aug; 16(31):e2001890. PubMed ID: 32608185
[TBL] [Abstract][Full Text] [Related]
3. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5.
Fang X; Xie H; Duan H; Li P; Yousaf M; Xu H; Yang Y; Wang C
PLoS One; 2017; 12(8):e0182697. PubMed ID: 28793338
[TBL] [Abstract][Full Text] [Related]
5. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
6. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
[TBL] [Abstract][Full Text] [Related]
7. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
8. Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer.
Fang X; Zhang K; Jiang M; Ma L; Liu J; Xu H; Yang Y; Wang C
Int J Pharm; 2021 Feb; 594():120183. PubMed ID: 33340596
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
10. CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia.
Xu S; Zhang M; Fang X; Hu X; Xing H; Yang Y; Meng J; Wen T; Liu J; Wang J; Wang C; Xu H
ACS Appl Mater Interfaces; 2022 Aug; 14(34):38584-38593. PubMed ID: 35977045
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia.
Yan D; Wei H; Lai X; Ge Y; Xu S; Meng J; Wen T; Liu J; Zhang W; Wang J; Xu H
J Control Release; 2020 Nov; 327():766-778. PubMed ID: 32949646
[TBL] [Abstract][Full Text] [Related]
12. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
13. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
14. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
Peled A; Tavor S
Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.
Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE
J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675
[TBL] [Abstract][Full Text] [Related]
16. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
Hu X; Mei S; Meng W; Xue S; Jiang L; Yang Y; Hui L; Chen Y; Guan MX
Cancer Lett; 2018 Jul; 425():1-12. PubMed ID: 29574276
[TBL] [Abstract][Full Text] [Related]
17. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.
Ieranò C; Portella L; Lusa S; Salzano G; D'Alterio C; Napolitano M; Buoncervello M; Macchia D; Spada M; Barbieri A; Luciano A; Barone MV; Gabriele L; Caraglia M; Arra C; De Rosa G; Scala S
Nanoscale; 2016 Apr; 8(14):7562-71. PubMed ID: 26983756
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
[TBL] [Abstract][Full Text] [Related]
19. A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia.
Xu X; Wang J; Tong T; Zhang W; Wang J; Ma W; Wang S; Zhou D; Wu J; Jiang L; Zhao M
Haematologica; 2022 Oct; 107(10):2344-2355. PubMed ID: 35295079
[TBL] [Abstract][Full Text] [Related]
20. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
